Form 4: Simulations Plus Director Walter Woltosz Sells Shares Under 10b5-1 Plan

Walter Woltosz, a director and 10% owner of Simulations Plus, sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 1, 2024, Walter S. Woltosz, a director and 10% owner of Simulations Plus, engaged in transactions involving the company's common stock.
• Woltosz acquired 735 shares as independent director compensation under the company's 2021 Equity Incentive Plan.
• He also sold 18,300 shares at an average price of $39.55 and 1,700 shares at an average price of $40.46.
• These sales were executed automatically under a Rule 10b5-1 plan.
• Following these transactions, Woltosz directly owns 3,521,592 shares of Simulations Plus common stock.
• Virginia E. Woltosz is also listed as a reporting person and 10% owner.
• Daniel Hoeft, attorney-in-fact, signed the form on behalf of Walter S. Woltosz and Virginia E. Woltosz.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there are insider sales, they are under a pre-arranged plan, mitigating negative implications. The acquisition of shares as compensation is a slightly positive sign.

Positives

• The acquisition of 735 shares as director compensation reflects continued alignment with the company's success.

Negatives

• The sale of 20,000 shares by a director and 10% owner could be perceived negatively by some investors, although it was conducted under a pre-arranged 10b5-1 plan.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes create short-term price volatility.
• There is always a risk that investors may interpret insider sales negatively, regardless of the circumstances.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider trading activity is always closely watched in the pharmaceutical software industry, as it can provide insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are common, allowing insiders to sell shares without being accused of acting on non-public information.

Comparison to Industry Standards

• Comparing insider trading activity to companies like Certara or Schrödinger would provide a benchmark, but this requires analyzing their respective Form 4 filings.
• The use of a 10b5-1 plan is a standard practice among executives and directors at publicly traded companies, including those in the software and pharmaceutical sectors.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan should reassure investors.
• The director compensation in the form of stock aligns the director's interests with those of the shareholders.

Key Dates